Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin dose comparison to prevent post-ERCP pancreatitis
ChiCTR2100051036Phase 4Completed
- Sponsor
- Shanghai Xuhui District Central Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Shanghai Xuhui District Central Hospital. Primary endpoint: Pancreatitis rate after ERCP. Started Sep 2021; status: completed.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on ChiCTR2100051036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051036.